Posted 03 September 2006 - 10:49 PM
Missed Demopression.
Peptides 1995;16(2):179-86
Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers.
Bruins J, Hijman R, Van Ree JM. Department of Pharmacology, Rudolf Magnus Institute, Utrecht, The Netherlands.
A single dose of DGAVP (2 mg) and a chronic treatment of 2 weeks (1 mg/day) were given to male and female volunteers by the intranasal route. Memory, mood, vigilance, and attention were tested starting 60 min after treatment. Initial storage of abstract words was improved in the males but not in the females after chronic treatment with DGAVP. This effect persisted after discontinuation of treatment. Initial storage and learning of concrete words were not affected by treatment with DGAVP. Chronic, but not acute, treatment with DGAVP reduced the reaction time for scanning of digits in a memory comparison task (Sternberg paradigm) in both sexes. No treatment effects were found for visual memory, vigilance, attention, mood, or blood pressure. The present study indicates a sexual dimorphism in the effect of DGAVP on certain memory processes.
Peptides 1992 May-Jun;13(3):461-8
Effect of a single dose of des-glycinamide-[Arg8]vasopressin or oxytocin on cognitive processes in young healthy subjects.
Bruins J, Hijman R, Van Ree JM. Department of Psychiatry, Utrecht, The Netherlands.
A single dose of des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal) or oxytocin (OXT, 20 IU intranasal) was given to female and male volunteers, respectively, in a placebo-controlled double-blind trial. Memory, vigilance, attention, and mood were tested starting 10 minutes after treatment. The DGAVP dose improved delayed recognition of abstract words when measured 1 week after treatment and reduced the intercept of a memory comparison task (Sternberg paradigm). A trend was present for DGAVP and OXT to affect learning, i.e., storage processes of verbal memory in an opposite way; DGAVP improved, while OXT attenuated initial storage and the rate of storage. No treatment effects on visual memory and vigilance were found. Of the mood measures, vigor was reduced immediately after treatment with OXT.
Neuropsychobiology 1990;23(2):82-8
Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects.
Bruins J, Kumar A, Schneider-Helmert D. Department of Psychology, University of Amsterdam, The Netherlands.
In 12 healthy student volunteers the influence on memory, attention and mood of a single dose of 2 mg of the vasopressin analog, desglycinamide-(arg8) vasopressin (DGAVP), given by the nasal route was investigated. On day 1 all subjects received placebo (single-blind), 1 week later they were given either DGAVP or placebo (double-blind). Memory effects were measured with the Buschke restrictive reminding method. DGAVP significantly improved storage processes, with retrieval processes less affected. Attention and mood processes were not influenced. It is suggested that DGAVP has an influence on memory processes.
Psychopharmacology (Berl) 1987;92(2):224-8
Does DGAVP influence memory, attention and mood in young healthy men?
Snel J, Taylor J, Wegman M.
The influence of an increasing dose of the vasopressin-like peptide DGAVP (desglycinamide-arginine-vasopressin) on memory was investigated in 2 groups of 10 healthy male volunteers to provide information about the hypothesis of improvement of memory by vasopressin. At the same time we evaluated the effect of DGAVP on mood, alertness or sleepiness in a double-blind placebo-control design. The treatment group received at 9.15 a.m. intranasally a daily increasing dose from 0.1 mg at day 1 to 10.0 mg at day 5. DGAVP did not significantly affect any measure of memory or alertness. DGAVP did, however, produce a significant increase in concentration level and mood. The results of the present study provide no support for the vasopressin theory of memory improvement; rather, the results direct the attention-to-attention modulating effects.
Peptides 1984 Jul-Aug;5(4):819-22
Vasopressin analog (DDAVP) improves memory in human males.
Beckwith BE, Till RE, Schneider V.
One specific analog of arginine vasopressin, 1-desamine-8-D-arginine vasopressin (DDAVP), has been shown to improve learning and memory in humans. Healthy young male adult subjects treated with DDAVP demonstrated better memory for implicational sentences than did control subjects. The same treatment had no influence on women given the same memory task. These results suggest that DDAVP may have a sexually dimorphic effect on learning and memory.
Peptides 1983 Sep-Oct;4(5):707-9
Vasopressin analog influences the performance of males on a reaction time task.
Beckwith BE, Couk DI, Till TS.
The effects of desmopressin acetate (DDAVP), a vasopressin analogue, were investigated using the Sternberg Item Recognition Task. This task requires a subject to memorize a target set of up to four digits and then quickly to decide whether or not a given probe was in the original memory set. 15 college aged males were used as subjects in this study. Subjects received, in a double blind procedure, 0.6 ml of DDAVP (60 micrograms) or an equal volume of vehicle solution during the first test session. One week later, during the second test session, the hormone-placebo treatments were reversed. The results indicated significant main effects for set size and decision type and an interaction between treatment and session. Treatment with DDAVP during the second but not the first session improved performance at each set size as compared to treatment with the vehicle. These results indicate that DDAVP, combined with experience on this task, improved attentional processes but did not influence memory, which would have been indicated by an interaction between treatment and size of memory set.
LongeCity
